Kala Pharmaceuticals Q2 EPS $(4.36) Up From $(18.92) YoY; $59.2M In Cash, Cash Equivalents And Short-Term Expected To Fund Operations Into 2Q 2025
Portfolio Pulse from Benzinga Newsdesk
Kala Pharmaceuticals reported Q2 losses of $(4.36) per share, a 76.96% increase from $(18.92) per share YoY. The company has $59.2M in cash, cash equivalents, and short-term expected to fund operations into 2Q 2025.
August 04, 2023 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kala Pharmaceuticals reported improved Q2 losses and has sufficient cash to fund operations into 2Q 2025.
Kala Pharmaceuticals reported a significant improvement in its Q2 losses compared to the same period last year. This, along with the company's strong cash position, is likely to be viewed positively by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100